AIMS: Lipoprotein-associated phospholipase A2 (Lp-PLA2) generates proinflammatory and proatherogenic compounds in the arterial vascular wall and is a potential therapeutic target in coronary heart disease (CHD). We searched for genetic loci related to Lp-PLA2 mass or activity by a genome-wide association study as part of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. METHODS AND RESULTS: In meta-analyses of findings from five population-based studies, comprising 13 664 subjects, variants at two loci (PLA2G7, CETP) were associated with Lp-PLA2 mass. The strongest signal was at rs1805017 in PLA2G7 [P = 2.4 × 10(-23), log Lp-PLA2 difference per allele (beta): 0.043]. Variants at six loci were associated with Lp-PLA2 activity (PLA2G7, APOC1, CELSR2, LDL, ZNF259, SCARB1), among which the strongest signals were at rs4420638, near the APOE-APOC1-APOC4-APOC2 cluster [P = 4.9 × 10(-30); log Lp-PLA2 difference per allele (beta): -0.054]. There were no significant gene-environment interactions between these eight polymorphisms associated with Lp-PLA2 mass or activity and age, sex, body mass index, or smoking status. Four of the polymorphisms (in APOC1, CELSR2, SCARB1, ZNF259), but not PLA2G7, were significantly associated with CHD in a second study. CONCLUSION: Levels of Lp-PLA2 mass and activity were associated with PLA2G7, the gene coding for this protein. Lipoprotein-associated phospholipase A2 activity was also strongly associated with genetic variants related to low-density lipoprotein cholesterol levels.
AIMS: Lipoprotein-associated phospholipase A2 (Lp-PLA2) generates proinflammatory and proatherogenic compounds in the arterial vascular wall and is a potential therapeutic target in coronary heart disease (CHD). We searched for genetic loci related to Lp-PLA2 mass or activity by a genome-wide association study as part of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. METHODS AND RESULTS: In meta-analyses of findings from five population-based studies, comprising 13 664 subjects, variants at two loci (PLA2G7, CETP) were associated with Lp-PLA2 mass. The strongest signal was at rs1805017 in PLA2G7 [P = 2.4 × 10(-23), log Lp-PLA2 difference per allele (beta): 0.043]. Variants at six loci were associated with Lp-PLA2 activity (PLA2G7, APOC1, CELSR2, LDL, ZNF259, SCARB1), among which the strongest signals were at rs4420638, near the APOE-APOC1-APOC4-APOC2 cluster [P = 4.9 × 10(-30); log Lp-PLA2 difference per allele (beta): -0.054]. There were no significant gene-environment interactions between these eight polymorphisms associated with Lp-PLA2 mass or activity and age, sex, body mass index, or smoking status. Four of the polymorphisms (in APOC1, CELSR2, SCARB1, ZNF259), but not PLA2G7, were significantly associated with CHD in a second study. CONCLUSION: Levels of Lp-PLA2 mass and activity were associated with PLA2G7, the gene coding for this protein. Lipoprotein-associated phospholipase A2 activity was also strongly associated with genetic variants related to low-density lipoprotein cholesterol levels.
Authors: Michael Preuss; Inke R König; John R Thompson; Jeanette Erdmann; Devin Absher; Themistocles L Assimes; Stefan Blankenberg; Eric Boerwinkle; Li Chen; L Adrienne Cupples; Alistair S Hall; Eran Halperin; Christian Hengstenberg; Hilma Holm; Reijo Laaksonen; Mingyao Li; Winfried März; Ruth McPherson; Kiran Musunuru; Christopher P Nelson; Mary Susan Burnett; Stephen E Epstein; Christopher J O'Donnell; Thomas Quertermous; Daniel J Rader; Robert Roberts; Arne Schillert; Kari Stefansson; Alexandre F R Stewart; Gudmar Thorleifsson; Benjamin F Voight; George A Wells; Andreas Ziegler; Sekar Kathiresan; Muredach P Reilly; Nilesh J Samani; Heribert Schunkert Journal: Circ Cardiovasc Genet Date: 2010-10-05
Authors: Thomas C Register; Kathryn P Burdon; Leon Lenchik; Donald W Bowden; Gregory A Hawkins; Barbara J Nicklas; Kurt Lohman; Fang-Chi Hsu; Carl D Langefeld; John J Carr Journal: Clin Chem Date: 2004-11 Impact factor: 8.327
Authors: S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann Journal: Am J Hum Genet Date: 2000-03-24 Impact factor: 11.025
Authors: Frank D Kolodgie; Allen P Burke; Kristi S Skorija; Elena Ladich; Robert Kutys; Addisalem Taye Makuria; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2006-09-07 Impact factor: 8.311
Authors: D M Stafforini; K Satoh; D L Atkinson; L W Tjoelker; C Eberhardt; H Yoshida; T Imaizumi; S Takamatsu; G A Zimmerman; T M McIntyre; P W Gray; S M Prescott Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett Journal: Circulation Date: 2004-02-02 Impact factor: 29.690
Authors: Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman Journal: Atherosclerosis Date: 2015-05-16 Impact factor: 5.162
Authors: Shobana Subramanian; William K Gottschalk; So Young Kim; Allen D Roses; Ornit Chiba-Falek Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-01-06 Impact factor: 5.187
Authors: Sylvia T Nurnberg; Hanrui Zhang; Nicholas J Hand; Robert C Bauer; Danish Saleheen; Muredach P Reilly; Daniel J Rader Journal: Circ Res Date: 2016-02-19 Impact factor: 17.367
Authors: Ron C Hoogeveen; John W Gaubatz; Wensheng Sun; Rhiannon C Dodge; Jacy R Crosby; Jennifer Jiang; David Couper; Salim S Virani; Sekar Kathiresan; Eric Boerwinkle; Christie M Ballantyne Journal: Arterioscler Thromb Vasc Biol Date: 2014-02-20 Impact factor: 8.311